National Cancer Center Hospital East, Kashiwa, Japan.
Yale School of Medicine and Yale Cancer Center, New Haven, CT, USA.
Target Oncol. 2024 Mar;19(2):131-134. doi: 10.1007/s11523-024-01034-3. Epub 2024 Mar 11.
This is a summary of the original article ‟Overall survival with osimertinib in resected EGFR-mutated NSCLC.ˮ Osimertinib blocks the activity of the epidermal growth factor receptor (EGFR) on cancer cells, causing cancer cell death and tumor shrinkage, and is an effective treatment for EGFR-mutated non-small cell lung cancer (NSCLC). The ADAURA study assessed the effects of osimertinib versus placebo in patients with EGFR-mutated (exon 19 deletion or L858R) early stage (IB-IIIA) NSCLC removed by surgery (resected). Previous results from ADAURA demonstrated that patients treated with osimertinib stayed alive and cancer-free (disease-free survival) significantly longer than patients who received placebo. Recent data showed the overall length of time patients were alive after starting treatment (overall survival). In both the primary stage II-IIIA and overall stage IB-IIIA populations, patients in the osimertinib group had a significant 51% reduction in the risk of death compared with the placebo group. The data demonstrated that osimertinib after surgery significantly improved overall survival in patients with resected, EGFR-mutated, stage IB-IIIA NSCLC.
这是对原始文章“奥希替尼治疗 EGFR 突变 NSCLC 的总生存期。”的摘要。奥希替尼可阻断癌细胞表皮生长因子受体（EGFR）的活性，导致癌细胞死亡和肿瘤缩小，是 EGFR 突变型非小细胞肺癌（NSCLC）的有效治疗方法。ADAURA 研究评估了奥希替尼与安慰剂在接受手术（切除）治疗的 EGFR 突变（外显子 19 缺失或 L858R）早期（IB-IIIA）NSCLC 患者中的疗效。ADAURA 的先前结果表明，接受奥希替尼治疗的患者无癌（无疾病生存期）存活时间明显长于接受安慰剂的患者。最近的数据显示了开始治疗后患者的总存活时间（总生存期）。在主要的 II-IIIA 期和整体的 IB-IIIA 期人群中，与安慰剂组相比，奥希替尼组患者的死亡风险降低了 51%。数据表明，奥希替尼在手术后显著改善了 EGFR 突变、IB-IIIA 期 NSCLC 患者的总生存期。
